Source:http://linkedlifedata.com/resource/pubmed/id/14578583
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2003-10-27
|
pubmed:abstractText |
At first, we investigated whether both beta-endorphin release level in the hypothalamus and body temperature can be altered after intracerebroventricular (i.c.v.) injection of either lipopolysaccharide (LPS), interleukin-1beta (IL-1beta), or prostaglandin E(2) (PGE(2)) in rats. It was found that in the rat, i.c.v. administration of either LPS (0.5 microg in 10 microl), IL-1beta (10 ng in 10 microl), or PGE(2) (200 ng in 10 microl), in addition to producing fever, upregulated the immunoreactivity of beta-endorphin in the preoptic anterior hypothalamus of rat brain. Secondarily, we assessed whether the fever induced by either LPS, IL-1beta, or PGE(2) can be altered by pretreatment with buprenorphine (an opioid receptor antagonist). The results revealed that i.c.v. administration of buprenorphine (1 - 10 microg in 10 microl) alone had an insignificant effect on the body temperature. However, the fever induced by i.c.v. injection of either LPS, IL-1beta, or PGE(2) was significantly attenuated by pretreatment with i.c.v. injection of buprenorphine 1 h before the pyrogen injection in rats. The results suggest that pyrogens enhance beta-endorphin release in the hypothalamus and trigger fever which can be attenuated by buprenorphine, an opioid receptor antagonist.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Buprenorphine,
http://linkedlifedata.com/resource/pubmed/chemical/Dinoprostone,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Lipopolysaccharides,
http://linkedlifedata.com/resource/pubmed/chemical/Narcotic Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrogens,
http://linkedlifedata.com/resource/pubmed/chemical/beta-Endorphin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1347-8613
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
93
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
155-62
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:14578583-Animals,
pubmed-meshheading:14578583-Buprenorphine,
pubmed-meshheading:14578583-Dinoprostone,
pubmed-meshheading:14578583-Fever,
pubmed-meshheading:14578583-Hypothalamus,
pubmed-meshheading:14578583-Immunohistochemistry,
pubmed-meshheading:14578583-Injections, Intraventricular,
pubmed-meshheading:14578583-Interleukin-1,
pubmed-meshheading:14578583-Lipopolysaccharides,
pubmed-meshheading:14578583-Male,
pubmed-meshheading:14578583-Narcotic Antagonists,
pubmed-meshheading:14578583-Pyrogens,
pubmed-meshheading:14578583-Rats,
pubmed-meshheading:14578583-Rats, Sprague-Dawley,
pubmed-meshheading:14578583-beta-Endorphin
|
pubmed:year |
2003
|
pubmed:articleTitle |
Pyrogens enhance beta-endorphin release in hypothalamus and trigger fever that can be attenuated by buprenorphine.
|
pubmed:affiliation |
Institute of Physiology, National Yang-Ming University Medical School, Taipei, Taiwan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|